Headlines

Eye Health Firm Acquired in $100M+ Deal

Published

5 years ago

August 21, 2018

It’s working on a glaucoma treatment.

TOKYO and CAMBRIDGE, ENGLAND — Tokyo-based Astellas Pharma Inc. has acquired Quethera Ltd., a U.K.-based gene therapy company that is developing treatments for ocular disorders such as glaucoma.

Astellas may pay up to £85 million (about $109.8 million at today’s exchange rate) to Quethera shareholders, including upfront and contingent amounts. Founded in 2013, Quethera has now become a wholly owned subsidiary of Astellas.

“Quethera’s novel technology approach is focused on exploring potential treatment options for common ophthalmic diseases, such as glaucoma, that can cause blindness and severely affect the quality of life for patients,” said Peter Widdowson, CEO of Quethera. “This deal enables us to accelerate our evaluation of this investigational technology program to see if we can slow or prevent disease progression for these patients.”

The acquisition includes Quethera’s ophthalmic gene therapy program. It “uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma,” according to a press release.

Success with the program “would address a high unmet medical need in glaucoma patients who are at risk of losing their eyesight,” said Kenji Yasukawa, president and CEO of Astellas.

Crizal® Sapphire™ HR: Invisible Shield of Protection

Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019.